article
Controlled clinical trial of cannabidiol in Huntington's disease
Pharmacology Biochemistry and Behavior · 1991 · Vol. 40(3) · pp. 701–708
Paul Consroe✉Joan Laguna(University of Arizona)James Allender(University of Arizona)Stuart R. Snider(University of Arizona)Lawrence Z. Stern(University of Arizona)Reuven Sandyk(University of Arizona)Kurt Kennedy(University of Arizona)Karl H. Schram(University of Arizona)
Genetic Neurodegenerative DiseasesCannabis and Cannabinoid ResearchParkinson's Disease Mechanisms and TreatmentsCannabidiolPlaceboCannabisMedicineChoreaInternal medicineClinical trialRandomized controlled trialAnesthesiaDisease
MeSH terms
AdolescentAdultAgedCannabidiolDouble-Blind MethodFemaleHumansHuntington DiseaseMaleMiddle AgedPsychomotor Performance
Funding
- U.S. Food and Drug Administration
- National Institute on Drug Abuse
Citations
315
FWCI
0.25
field-weighted impact
References
29
Percentile
42%
vs. same field & year
Citations per year
Cited by
Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?
British Journal of Clinical Pharmacology · 2012 · 340 citations
The pharmacokinetics and the pharmacodynamics of cannabinoids
British Journal of Clinical Pharmacology · 2018 · 671 citations
References
Nonparametric statistics for the behavioral sciences
Journal of the Franklin Institute · 1957 · 7,279 citations
Evaluating storage, retention, and retrieval in disordered memory and learning
Neurology · 1974 · 1,614 citations
The SCL-90 and the MMPI: A Step in the Validation of a New Self-Report Scale
The British Journal of Psychiatry · 1976 · 2,293 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.